SHIRE PHARMACEUTICALS LLC — Lobbying Disclosure | Poliscope

SHIRE PHARMACEUTICALS LLC

View full entity profile (contributions, contracts, SEC) →

This entity appears on both sides of lobbying disclosures. The firm tab shows registrant-reported income; the client tab shows client-reported lobbying spend. Contract awards are separate and are not included here.

Lobbying Spend

$13.7M

Filings

Firms Hired

Active Period

2007–2019

Lobbying Spend by Year

Client-reported lobbying expenses on LDA filings

Year	Lobbying Spend	Filings	Firms
2019	$110,000	2	2
2018	$1,740,000	15	4
2017	$3,260,000	20	4
2016	$1,550,000	16	4
2015	$1,480,000	9	2
2014	$1,790,000	5	1
2013	$1,120,000	5	1
2012	$550,000	5	1
2011	$370,000	4	1
2010	$530,000	5	1
2009	$450,000	4	1
2008	$491,000	4	1
2007	$250,000	4	1

Hired Firms

Lobbying firms retained by this client; amounts are client-reported expenses when available

Firm Name	Reported Spend	Filings
SHIRE PHARMACEUTICALS LLC	$13,691,000	55
THE NICKLES GROUP, LLC	—	14
SIDLEY AUSTIN LLP	—	12
STANTON PARK GROUP	—	13
THE WATTS GROUP PLLC	—	4

Government Bodies Lobbied

Government entities explicitly identified as targets in LDA filings

Government Body	Filings
SENATE	82
HOUSE OF REPRESENTATIVES	73
Centers For Medicare and Medicaid Services (CMS)	8
Food & Drug Administration (FDA)	7
Natl Institutes of Health (NIH)	4
Office of the Vice President of the United States	4
Congressional Budget Office (CBO)	2
Drug Enforcement Administration (DEA)	2
Executive Office of the President (EOP)	2
Health & Human Services, Dept of (HHS)	2
Office of Management & Budget (OMB)	2
Government Accountability Office (GAO)	1
Natl Economic Council (NEC)	1
Office of Natl Drug Control Policy (NDCP)	1
Veterans Affairs, Dept of (VA)	1

Top Issues

Most frequently reported lobbying issues

Issue Code	Description	Reports
Health Issues	Health Issues	66
Pharmacy	Pharmacy	48
Medicare/Medicaid	Medicare/Medicaid	39
Taxation/Internal Revenue Code	Taxation/Internal Revenue Code	26
Medical/Disease Research/Clinical Labs	Medical/Disease Research/Clinical Labs	7
Budget/Appropriations	Budget/Appropriations	6
Copyright/Patent/Trademark	Copyright/Patent/Trademark	4
Trade (domestic/foreign)	Trade (domestic/foreign)	4
Foreign Relations	Foreign Relations	3

Bills Explicitly Cited (25)

Bill numbers found in source-reported LDA specific issue text; broad topic matches are excluded

H.R. 4724115th Congress

Medicare IVIG Access Enhancement Act

2018 · third_quarter · Firm: THE WATTS GROUP PLLC

Open original LDA filing ↗

Cited source text and reported amounts

S. 1194, Medical Nutrition Equity Act; H.R. 4724

Client expense: — · Firm income: $60,000

Matched citations: H.R. 4724

H.R. 4724115th Congress

Medicare IVIG Access Enhancement Act

2018 · third_quarter · Firm: THE WATTS GROUP PLLC

Open original LDA filing ↗

Cited source text and reported amounts

S. 1194, Medical Nutrition Equity Act; H.R. 4724, Medicare IVIG Access Enhancement Act

Client expense: — · Firm income: $60,000

Matched citations: H.R. 4724

S. 1194115th Congress

Medical Nutrition Equity Act of 2017

2018 · third_quarter · Firm: THE WATTS GROUP PLLC

Open original LDA filing ↗

Cited source text and reported amounts

S. 1194, Medical Nutrition Equity Act; H.R. 4724

Client expense: — · Firm income: $60,000

Matched citations: S. 1194

S. 1194115th Congress

Medical Nutrition Equity Act of 2017

2018 · third_quarter · Firm: THE WATTS GROUP PLLC

Open original LDA filing ↗

Cited source text and reported amounts

S. 1194, Medical Nutrition Equity Act; H.R. 4724, Medicare IVIG Access Enhancement Act

Client expense: — · Firm income: $60,000

Matched citations: S. 1194

Show 21 more cited filings

H.R. 4274115th Congress

Higher Education Reform and Opportunity Act of 2017

2018 · fourth_quarter · Firm: THE WATTS GROUP PLLC

Open original LDA filing ↗

Cited source text and reported amounts

S. 1194, Medical Nutrition Equity Act; H.R. 4274, Medicare IVIG Access Enhancement Act

Client expense: — · Firm income: $60,000

Matched citations: H.R. 4274

H.R. 4724115th Congress

Medicare IVIG Access Enhancement Act

2018 · fourth_quarter · Firm: THE WATTS GROUP PLLC

Open original LDA filing ↗

Cited source text and reported amounts

S. 1194, Medical Nutrition Equity Act; H.R. 4724, Medicare IVIG Access Enhancement Act

Client expense: — · Firm income: $60,000

Matched citations: H.R. 4724

S. 1194115th Congress

Medical Nutrition Equity Act of 2017

2018 · fourth_quarter · Firm: THE WATTS GROUP PLLC

Open original LDA filing ↗

Cited source text and reported amounts

S. 1194, Medical Nutrition Equity Act; H.R. 4274, Medicare IVIG Access Enhancement Act

Client expense: — · Firm income: $60,000

Matched citations: S. 1194

S. 1194115th Congress

Medical Nutrition Equity Act of 2017

2018 · fourth_quarter · Firm: THE WATTS GROUP PLLC

Open original LDA filing ↗

Cited source text and reported amounts

S. 1194, Medical Nutrition Equity Act; H.R. 4724, Medicare IVIG Access Enhancement Act

Client expense: — · Firm income: $60,000

Matched citations: S. 1194

H.R. 4724115th Congress

Medicare IVIG Access Enhancement Act

2018 · third_quarter · Firm: THE WATTS GROUP PLLC

Open original LDA filing ↗

Cited source text and reported amounts

S. 1194, Medical Nutrition Equity Act; H.R. 4724, Medicare IVIG Access Enhancement Act

Client expense: — · Firm income: —

Matched citations: H.R. 4724

H.R. 4724115th Congress

Medicare IVIG Access Enhancement Act

2018 · third_quarter · Firm: THE WATTS GROUP PLLC

Open original LDA filing ↗

Cited source text and reported amounts

S. 1194, Medical Nutrition Equity Act; H.R. 4724, Medicare IVIG Access Enhancement Act

Client expense: — · Firm income: —

Matched citations: H.R. 4724

S. 1194115th Congress

Medical Nutrition Equity Act of 2017

2018 · third_quarter · Firm: THE WATTS GROUP PLLC

Open original LDA filing ↗

Cited source text and reported amounts

S. 1194, Medical Nutrition Equity Act; H.R. 4724, Medicare IVIG Access Enhancement Act

Client expense: — · Firm income: —

Matched citations: S. 1194

S. 1194115th Congress

Medical Nutrition Equity Act of 2017

2018 · third_quarter · Firm: THE WATTS GROUP PLLC

Open original LDA filing ↗

Cited source text and reported amounts

S. 1194, Medical Nutrition Equity Act; H.R. 4724, Medicare IVIG Access Enhancement Act

Client expense: — · Firm income: —

Matched citations: S. 1194

H.R. 6114th Congress

21st Century Cures Act

2018 · fourth_quarter · Firm: SHIRE PHARMACEUTICALS LLC

Open original LDA filing ↗

Cited source text and reported amounts

- Home Infusion technical change to H.R.6 21st Century Cures to move wrap around training and monitoring services benefit forward from 2021 to 2018 implementation. - Medicare coverage and reimbursement - Medicare Part B drug payment model demonstration - HR 4724: Medicare IVIG Access Enhancement Act - Medicare Part D

Client expense: $230,000 · Firm income: —

Matched citations: H.R.6

H.R. 2587115th Congress

Medical Nutrition Equity Act of 2017

2018 · fourth_quarter · Firm: SHIRE PHARMACEUTICALS LLC

Open original LDA filing ↗

Cited source text and reported amounts

HR 2587/S1194: Medical Nutrition Equity Act of 2017 HR6: Support for Patients and Communities Act 340B Drug Discount Program Orphan Drug Act Gene Therapy Drug Pricing

Client expense: $230,000 · Firm income: —

Matched citations: HR 2587

H.R. 4724115th Congress

Medicare IVIG Access Enhancement Act

2018 · fourth_quarter · Firm: SHIRE PHARMACEUTICALS LLC

Open original LDA filing ↗

Cited source text and reported amounts

- Home Infusion technical change to H.R.6 21st Century Cures to move wrap around training and monitoring services benefit forward from 2021 to 2018 implementation. - Medicare coverage and reimbursement - Medicare Part B drug payment model demonstration - HR 4724: Medicare IVIG Access Enhancement Act - Medicare Part D

Client expense: $230,000 · Firm income: —

Matched citations: HR 4724

H.R. 5340115th Congress

STRONGER Patents Act of 2018

2018 · fourth_quarter · Firm: SHIRE PHARMACEUTICALS LLC

Open original LDA filing ↗

Cited source text and reported amounts

HR 5340/S1390: Stronger Patents Act

Client expense: $230,000 · Firm income: —

Matched citations: HR 5340

H.R. 6115th Congress

SUPPORT for Patients and Communities Act

2018 · fourth_quarter · Firm: SHIRE PHARMACEUTICALS LLC

Open original LDA filing ↗

Cited source text and reported amounts

HR 2587/S1194: Medical Nutrition Equity Act of 2017 HR6: Support for Patients and Communities Act 340B Drug Discount Program Orphan Drug Act Gene Therapy Drug Pricing

Client expense: $230,000 · Firm income: —

Matched citations: HR6

S. 1194115th Congress

Medical Nutrition Equity Act of 2017

2018 · fourth_quarter · Firm: SHIRE PHARMACEUTICALS LLC

Open original LDA filing ↗

Cited source text and reported amounts

HR 2587/S1194: Medical Nutrition Equity Act of 2017 HR6: Support for Patients and Communities Act 340B Drug Discount Program Orphan Drug Act Gene Therapy Drug Pricing

Client expense: $230,000 · Firm income: —

Matched citations: S1194

S. 1390115th Congress

STRONGER Patents Act of 2017

2018 · fourth_quarter · Firm: SHIRE PHARMACEUTICALS LLC

Open original LDA filing ↗

Cited source text and reported amounts

HR 5340/S1390: Stronger Patents Act

Client expense: $230,000 · Firm income: —

Matched citations: S1390

H.R. 3325115th Congress

ACE Kids Act

2018 · fourth_quarter · Firm: THE NICKLES GROUP, LLC

Open original LDA filing ↗

Cited source text and reported amounts

Issues related to pharmaceutical prices. H.R. 6, SUPPORT for Patients and Communities Act; S.2680, Opioid Crisis Response Act of of 2018 and issues related to controlled substances; monitored S. 2554 / H.R. 6143, the Patient Right to Know Drug Prices Act; monitored H.R. 3325, the Advancing Care for Exceptional Kids Act (ACE Kids) and H.R. 7212, IMPROVE Act. S. 1194, Medical Nutrition Equity Act. H.R. 4724, Medicare IVIG Access Enhancement Act.

Client expense: — · Firm income: $52,500

Matched citations: H.R. 3325

H.R. 4724115th Congress

Medicare IVIG Access Enhancement Act

2018 · fourth_quarter · Firm: THE NICKLES GROUP, LLC

Open original LDA filing ↗

Cited source text and reported amounts

Issues related to pharmaceutical prices. H.R. 6, SUPPORT for Patients and Communities Act; S.2680, Opioid Crisis Response Act of of 2018 and issues related to controlled substances; monitored S. 2554 / H.R. 6143, the Patient Right to Know Drug Prices Act; monitored H.R. 3325, the Advancing Care for Exceptional Kids Act (ACE Kids) and H.R. 7212, IMPROVE Act. S. 1194, Medical Nutrition Equity Act. H.R. 4724, Medicare IVIG Access Enhancement Act.

Client expense: — · Firm income: $52,500

Matched citations: H.R. 4724

H.R. 5803115th Congress

SAFETY Act of 2018

2018 · fourth_quarter · Firm: THE NICKLES GROUP, LLC

Open original LDA filing ↗

Cited source text and reported amounts

Orphan Drug Act and issues regarding access to care for those with rare diseases. H.R. 5803, SAFETY Act of 2018, S. 2680, Opioid Crisis Response Act of 2018, S. 2891, Fighting the Opioid Epidemic with Sunshine Act of 2018, S. 3000, Patient Advocacy Transparency Act, and H.R. 6, SUPPORT for Patients and Communities Act as they related to issues regarding controlled substances. Monitored issues related to newborn screening.

Client expense: — · Firm income: $52,500

Matched citations: H.R. 5803

H.R. 6115th Congress

SUPPORT for Patients and Communities Act

2018 · fourth_quarter · Firm: THE NICKLES GROUP, LLC

Open original LDA filing ↗

Cited source text and reported amounts

Issues related to pharmaceutical prices. H.R. 6, SUPPORT for Patients and Communities Act; S.2680, Opioid Crisis Response Act of of 2018 and issues related to controlled substances; monitored S. 2554 / H.R. 6143, the Patient Right to Know Drug Prices Act; monitored H.R. 3325, the Advancing Care for Exceptional Kids Act (ACE Kids) and H.R. 7212, IMPROVE Act. S. 1194, Medical Nutrition Equity Act. H.R. 4724, Medicare IVIG Access Enhancement Act.

Client expense: — · Firm income: $52,500

Matched citations: H.R. 6

H.R. 6115th Congress

SUPPORT for Patients and Communities Act

2018 · fourth_quarter · Firm: THE NICKLES GROUP, LLC

Open original LDA filing ↗

Cited source text and reported amounts

Orphan Drug Act and issues regarding access to care for those with rare diseases. H.R. 5803, SAFETY Act of 2018, S. 2680, Opioid Crisis Response Act of 2018, S. 2891, Fighting the Opioid Epidemic with Sunshine Act of 2018, S. 3000, Patient Advocacy Transparency Act, and H.R. 6, SUPPORT for Patients and Communities Act as they related to issues regarding controlled substances. Monitored issues related to newborn screening.

Client expense: — · Firm income: $52,500

Matched citations: H.R. 6

H.R. 6143115th Congress

Patient Right to Know Drug Prices Act

2018 · fourth_quarter · Firm: THE NICKLES GROUP, LLC

Open original LDA filing ↗

Cited source text and reported amounts

Issues related to pharmaceutical prices. H.R. 6, SUPPORT for Patients and Communities Act; S.2680, Opioid Crisis Response Act of of 2018 and issues related to controlled substances; monitored S. 2554 / H.R. 6143, the Patient Right to Know Drug Prices Act; monitored H.R. 3325, the Advancing Care for Exceptional Kids Act (ACE Kids) and H.R. 7212, IMPROVE Act. S. 1194, Medical Nutrition Equity Act. H.R. 4724, Medicare IVIG Access Enhancement Act.

Client expense: — · Firm income: $52,500

Matched citations: H.R. 6143

Source: Senate LDA